Author Archives: Yedida Y Bogachkov PhD

CTH120 Medication Granted Orphan Designation in EU

Connecta Therapeutics‘ CTH120 molecule has been granted orphan designation by the European Medicines Agency (EMA) for treating fragile X syndrome, the leading cause of hereditary intellectual disability and autism spectrum disorders. The company said it intends to begin human clinical trials as early as next year to test …